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Background: Preliminary, mostly uncontrolled studies suggest that dose reduction or discontinuation of tumour
necrosis factor blockers can be achieved in a relevant proportion of patients with RA without loss of disease
control. However, long term safety, cost effectiveness and feasibility in clinical practice remain uncertain.
Methods/Design: This study is a 18-months pragmatic, non-inferiority, cost minimalisation, randomized controlled
trial on dose reduction and discontinuation of the subcutaneous tumour necrosis factor (TNF) blockers adalimumab
and etanercept in RA patients with low disease activity. 180 RA patients with low disease activity (DAS28 < 3.2 or
clinical judgment of the rheumatologist) are randomized 2:1 to either increased spacing and eventually
discontinuation after 6 months of the TNF blocker, and usual care. Implementation is done in routine daily care,
using treat to target and feedback implementation in both treatment arms. The primary outcome is non-inferiority
(NI margin 20%) in cumulative incidence of persistent (> 3 months) RA flare, according to a recently validated
DAS28 based flare criterion (DAS28 change > 1.2, or DAS28 increase of 0.6 and current DAS28 ≥ 3.2). Secondary
outcomes include mean disease activity, function, radiographic progression, safety and cost effectiveness. Cost per
quality adjusted life year (QALY) differences between groups are expressed as a decremental cost effectiveness ratio
(DCER), i.e. saved costs divided by (possible) loss in QALY.
Discussion: The design of this study targeted several clinical and methodological issues on TNF blocker dose
de-escalation, including how to taper the TNF blockers, the satisfactory control condition, how to define flare,
implementation in clinical practice, and the choice of the non-inferiority margin. Pragmatic cost minimalisation
studies using non-inferiority designs and DCERs will become more mainstream as cost effectiveness in healthcare
gains importance.
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Tumour necrosis factor blocking agents (TNF-blockers)
have proven to be effective and safe pharmacological in-
terventions in the treatment of rheumatoid arthritis
(RA). As these agents improve clinical, functional and
radiographic outcome, TNF-blockers have become an
integral part of the standard of care of RA. However,
TNF-blockers are also associated with (sometimes dose
dependant) adverse effects including injection site reac-
tions, increased risk of infections and non melanoma
skin cancer/lymphomas, rare severe adverse events and
high costs [1-3]. Optimal use of these drugs is therefore
warranted, including the right dose for the right patient
[4]. Elective dose reduction in the context of low disease
activity is however up to recently very uncommon in
daily clinical practice [5].
Emerging data, mostly uncontrolled, has indicated that
dose reduction or discontinuation of TNF blockers [6-20]
can be achieved in a relevant proportion of patients with
RA without loss of disease control. This seems similar be-
tween the three most used anti-TNF agents infliximab,
adalimumab and etanercept (no data are available on
certolizumab and golimumab), although the proportion of
patients in whom the drug can be safely tapered seems to
depend on the design of the study and context (especially
authorized or higher than authorized dosage, dose reduc-
tion or stopping, and in early or established RA).
The fact that dose reduction or discontinuation can be
successful could be expected for several reasons [4]. In
clinical phase II/III studies, lower than registered anti-
TNF dosages have been shown to result in good re-
sponse in sizable proportions of patients [21-23]. So,
maintenance of clinical efficacy on lower dosages is to
be expected in many patients. In addition, patients
sometimes improve independently of the installed treat-
ment, as witnessed by the improvement that is found in
placebo arms of clinical trials [21-23]. This improve-
ment is in part spontaneous improvement (regression to
the mean) or due to concomitant DMARD or gluco-
corticoid therapy, but also caused by the placebo effect
(expectation bias) [24].
Although data on dose reduction is increasing, a num-
ber of aspects of dose tapering strategies in TNF blockers
are still not well known thus far. Is reinstallment of the
TNF blocker safe and effective? Is reducing the dose while
maintaining clinical response associated with more radio-
graphic joint damage in the long-term? Can these strat-
egies be implemented in daily clinical care, and what is
the cost effectiveness compared to usual care? To answer
these questions, we designed a pragmatic RCT, the results
of which will be presented in a separate paper. The pri-
mary aim of this study is to demonstrate non-inferiority of
a dose reduction strategy compared to usual care with re-
gard to persistent disease flare.During the design of this RCT, a number of issues had
to be addressed and in this paper we would like to de-
scribe in detail the study design, and motivate and dis-
cuss some of the design choices that were made.
Methods/Design
This pragmatic, open, randomised, controlled, stratified
non-inferiority strategy trial with cost effectiveness analysis
is currently being performed (inclusion finished October
2012) at the departments of rheumatology of the Sint
Maartenskliniek in the cities of Nijmegen and Woerden,
the Netherlands. The study has received ethical review
board approval (number NL37704.091.11) and has been
registered (Dutch Trial Register NTR3216). A data safety
monitoring board (DSMB) is installed. Every three months
data on recruitment, efficacy, safety, protocol adherence
and protocol updates and all aspects concerning GCP
are reviewed with three independent DSMB members,
an internal medicin physician, a pharmacist and an
epidemiologist.
We made a distinction in an induction phase (months
0-9 after the first dose reduction) and a maintenance phase
(months 6-18), because the cost effectiveness is very dif-
ferent between these two time periods [14] (Figure 1). In
the induction phase, medication costs are still high, pa-
tients are sometimes seen more often, and quality of life
might be compromised by temporary flares. Therefore,
the cost effectiveness ratio found in the stable mainten-
ance phase can be better interpreted for subsequent years.
Objectives
The aim of the study is to test whether a tight control
strategy with protocollised dose reduction and discontinu-
ation in RA patients using TNF blockers is non-inferior
with regard to disease control compared to a strategy
without dose reduction attempt, and superior with regard
to cost effectiveness. This translates in the following re-
search questions:
Primary objective
– To assess whether the difference in cumulative incidence
in persistent RA flares with a duration > 3 months
between the intervention group and the usual care
group of RA patients does not exceed the non-
inferiority margin of 20% after 18 months of
follow up.
Secondary objectives
– To compare the cumulative incidence of patients
fulfilling flare criteria in the intervention and the
usual care group after 9 months and after
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Figure 1 Design of the induction and maintenance phase.
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with persistent RA flare resulting in change of
biological between the intervention and the usual
care group after 9 months and after 18 months of
follow up.
– To compare the proportion of patients with a
DAS28 < 3.2, DAS28 < 2.6 and fulfilling remission
criteria according to ACR/EULAR criteria between
the intervention and usual care group at 9 and
18 months follow up.
– To compare the mean DAS28 and the mean time
averaged DAS28 between the intervention and usual
care group at 9 and 18 months follow up.
– To compare the proportion of patients using
NSAIDs, glucocorticoids or DMARDs between the
intervention and usual care group at 9 and
18 months follow up.
– To compare the mean Health assessment
questionnaire disability index (HAQ-DI) between
intervention and usual care group at 9 and
18 months follow-up.
– To compare the proportion of patients with a
change in modified Sharp-van der Heijde Score
exceeding the minimal clinical important change
(MCIC) between the intervention and usual care
group at 18 months.
– To compare the proportion of patients developing
adverse events with special attention for allergic/
injection reactions between the intervention and
usual care group.
– To estimate the decremental cost effectiveness
ratio of a protocollised dose reduction/withdrawal strategy of adalimumab or etanercept
compared to usual care for the 9 months
induction phase and for the 12 months
maintenance phase.
Study design rationale
The comparison made in this study is between usual
care and an alternative strategy (dose reduction) that
aims to preserve, but not improve, disease control,
whilst minimising the amount of TNF blocker. There-
fore, a non-inferiority design (“can we achieve the same
effect with less effort”) instead of the classic superiority
RCT design (“can we do better with more effort”) was
chosen. Of note, this is an adaptation of the original reg-
istered research protocol.
Study outcome rationale
As disease control is the domain that should remain
non-inferior, an outcome measure of disease control had
to be selected as primary outcome. Several options come
to mind, each with specific advantages and drawbacks.
A straightforward option would be a comparison of
disease activity at study end, like for example mean
DAS28 with non-inferiority margin of 0.3 DAS28 points.
However, it can be expected that at study end no differ-
ence is found between the two strategies because pa-
tients are treat-to-target, but that flaring is much more
frequent during the study in the dose reduction arm.
Comparison of time integrated DAS28 might be there-
fore a better alternative, with the bonus of lower sample
size requirements due to the repeated measurements
[18]. However, disease activity AUC values are harder to
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than percentage of patients with a flare. The latter also
facilitates the calculation of numbers needed to treat/
harm (NNT/NNH), thus making results easier to inter-
pret and communicate to patients and physicians alike.
Another option would therefore be to use cumulative
incidence of flares as primary outcome, and this is
chosen in the majority of dose reduction and discontinu-
ation studies. However, temporary flares that improve
after reinstallment of therapy and without a large impact
on overall disease control will inevitably occur more fre-
quent in a dose reduction arm, but are clinically less
relevant than persisting flares. We therefore chose to as-
sess non-inferiority with respect to cumulative incidence
of persisting flare, which is defined as a flare according
to the DAS28 based OMERACT validated flare criterion
persisting for at least 3 months (independent of treat-
ment changes).
An interesting alternative for a primary outcome of
non-inferior disease control would be to prove superior
cost effectiveness of the alternative strategy. This would
require proving that either the alternative strategy does
not lead to loss of Quality Adjusted LifeYears (QALY)
but saves costs (dominant strategy), or that the ratio of
saved costs and loss of QALY is favourable. Of note,
instead of the common term incremental cost effective-
ness ratio (ICER), this approach results in a decremental
cost effectiveness ratio (DCER), that states the amount
of costs saved per lost QALY. The use of this kind of
analyses as primary research question is however challen-
ging due to several issues, and therefore very infrequently
employed [25]. Firstly, due to the bootstrapping methods
that are used to calculate the DCER, a formal sample size
calculation is not possible. Secondly, quality of life is only
moderately correlated with RA disease activity, posing a
real chance of false reinsurance when quality of life does
not seem to be compromised. Thirdly, although ICERs of
under 40.000 euro per gained QALY are widely accepted
as cost-effective , no such clear-cut threshold is available
for DCERs. Although the symmetry of using also 40.000
as threshold for DCER seems attractive, as these saved cost
can be used elsewhere in health care system to get more
quality of life improvement than was lost, it seems awkward
to provide suboptimal therapy in relatively low cost effect-
iveness ranges. However, it can be argued that when the
situation was reversed, e.g., when usual care would be to
attempt dose reduction, the alternative of continuing
medication would not be considered cost-effective when
data shows an ICER clearly over 40.000. Interpretation of
DCER seems therefore coloured by anchoring to either the
existing and/or the alternative strategy. Anyway, a high
DCER of for example > 100.000 saved per lost QALY
would probably meet wide acceptance from a cost effective-
ness point of view [25].Patients, eligibility and generalisability
All patients are eligible to enter the study if they are
diagnosed with rheumatoid arthritis (either 2010 ACR
RA and/or 1987 RA criteria and/or clinical diagnosis
of the treating rheumatologist, fulfilled at any time
point between start of the disease and inclusion), and
of any disease duration, use etanercept or adalimumab
in any stable dose for at least 6 months, and are in
low disease activity state [26,27]. Previous dose reduc-
tion of the TNF blocker is allowed when more than
6 months ago. All background medication including
DMARDs (either monotherapy or in combination) and
prednisone equivalent up to 5 mg are allowed during
the study and have to be stable for at least four weeks
before inclusion. Consenting patients are randomly
allocated in a ratio of 2:1 to the intervention or the
control group, stratified for TNF blocker (adalimumab
and etanercept).
We have chosen to operationalise low disease activity
state by either a DAS28CRP < 3.2 or judgment of low
disease activity by the rheumatologist at two subsequent
visits at least 3 month apart. This means also patients
with a DAS28 ≥ 3.2, but judged to have a low disease ac-
tivity by their treating rheumatologist, are eligible for in-
clusion. This is firstly because several biologic registries
show that mean DAS28 in TNF Blocker treated patients
in clinical practice is around 3.2 [28]. This means that
over 50% of the patients has a DAS28 ≥ 3.2, and even
more are not in remission, but that both the patient and
rheumatologist judge the disease activity to be low
enough not to warrant switch of treatment. Limiting in-
clusion to only patients with DAS28 < 3.2 or even < 2.6
would therefore limit generalisability to current treat-
ment practices. It might be rebutted that these higher
disease activity scores reflect undertreatment and thus
result in suboptimalisation. A DAS28 can however be in-
flated by OA associated joint pain, concomitant fibro-
myalgia or spuriously elevated ESR. This is also the
rationale for use of DAS28CRP instead of DAS28 ESR.
Another important consideration is that we treat RA pa-
tients for two reasons: firstly to improve current signs
and symptoms, and secondly to prevent joint damage.
With respect to the first reason, it is important to note
that the patient acceptable symptom state of the DAS28,
has been found to be around 3.5 to 3.9, clearly higher
than the currently advocated treatment aims of 2.6 or
3.2 [29]. For prevention of joint damage it is important
to realize that not all patients have high risk of erosive
disease and a need for prognosis modification [30].
Therefore, accepting somewhat higher disease activity
can be legitimate and is indeed part of clinical practice.
Of note, per October 19, 2012, all patients (n = 180)
have been enrolled and randomised. Mean DAS28CRP is
2.2, and 8% of patients had a DAS28 > 3.2.
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chose to only exclude patients if they have co mor-
bidity which also requires treatment with anti-TNF
and thus prevents dose reduction (e.g. Crohns dis-
ease), or when it is to be expected that the outcome
cannot be measured (short life expectancy, planned
major surgery).Interventions
Control
Patients in the usual care group will continue treatment
by their own rheumatologist, following a standardized
protocol based on the tight control/treat-to-target prin-
ciple and aiming to maintain low disease activity. Visits
are planned every 3 months and patients are encouraged
to contact the outpatient clinic if they experience more
complaints in between visits. CRP based DAS28 mea-
surements are provided on the day of the outpatient visit
to the treating rheumatologists. The standardized pro-
tocol offers protocollised treatment suggestions when
there is a flare, including a treatment algorithm and dos-
ing of the drugs. The research physician monitors proto-
col adherence of the rheumatologists and will - where
needed - give feedback and advice to the rheumatologist.
Treatment choices, however, are left to the discretion of
the treating rheumatologist. This way it is ensured that
positive study results can be achieved also in clinical
practice. Treatment will be changed in case of a con-
firmed flare (the definition of flare will be discussed sep-
arately). A one time flare will be, if necessary, bridged
with glucocorticoids. Also, dose reduction or stopping,
for any reason, was allowed in the control arm, as this is
sometimes-although infrequent-also part of usual care
(5). In summary, the control condition exist of tight con-
trol by patients own rheumatologist, and all treatment
choices are allowed.
Of note, although called usual care, tight control care
has thus far not consistently been implemented in clin-
ical care in the Netherlands [31]. However, opting for a
standard care arm without tight control would result in
underestimation of possible drawbacks of dose reduc-
tion, as these effects would be ameliorated by the differ-
ence in tight control.Intervention
The intervention group receives identical care as the
control group, with addition of a dose reduction and
withdrawal strategy protocol and feedback and advice to
treating rheumatologist. This strategy is directly adapted
from the Dutch Society of Rheumatology biological
guideline [32]. If a patient uses adalimumab, the interval
will be stepwise increased every three months from 14
to 21 to 28 days, after that the adalimumab will bestopped. For etanercept, the interval will be increased
from 7 to 10 to 14 days and stopped thereafter. If a pa-
tient uses a different dose regimen at start, an alternative
dose reduction strategy is used. Patients already on a
longer dosing interval will step in at the nearest dosing
interval. Patients on a shorter dosing interval will also
stepwise increase the interval to stop after 6 months
using an accelerated strategy. The three month interval
is based on data that shows that most of the flaring after
dose reduction occurs within 3 months [14].
The dose reduction steps from 100% to 66% and 50%
and thereafter stop are based on the notion that rela-
tively small dose reduction seems to be feasible in a
large proportion of patients, and therefore will lead to
sizable reduction in total volume and costs of the TNF
blocker [14,20]. Indeed, although stopping the TNF
blocker obviously saves more drug per patient than dose
reduction, the total volume of saved drugs is the same in
patients that stop or are only dose reduced, because the
latter group is much larger [14]. Also, although we can-
not substantiate this, dose reduction until stop feels
more appropriate for patients than just stopping the
drug.
When a confirmed flare occurs, the interval is de-
creased back to the last effective interval. When there is
still no improvement of disease activity eventually after
reintroduction of the original interval and dose, the pa-
tient will be advised to switch to the next biologic or
DMARD according to the treatment protocol.
Outcome measures
The outcome measures used in this study include dis-
ease activity (DAS28CRP based RA Flare criterion, mean
and time integrated DAS28CRP), function (HAQ DI),
radiological damage (Modified Sharp van der Heijde
score, MSvdH), Adverse events (CTC 4.0 criteria), utility
(Euroqol 5D 5 L) and costs [33-39].
Definition of flare
RA Flare in this study is defined in both treatment arms
as a DAS28 increase compared to baseline of more than
1.2 or a DAS28 increase of more than 0.6 with a current
DAS28 ≥ 3.2 at two separate timepoints at least 4 weeks
apart. This criterion has been validated recently, and has
been shown to have the optimal tradeoff between sensi-
tivity and specificity, and the best construct and criterion
validity [40]. As it has been shown that flares are fre-
quently temporary and occur and disappear without
regimen change, a flare is only considered a flare if it is
confirmed after at least 4 weeks [11]. Patients are how-
ever not left untreated, and when a flare in disease activity
occurs, all bridging therapy including i.a. or im steroids or
NSAID can be given and are allowed. Of note, flares are
defined with change compared to baseline, not compared
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a slight increase in disease in subsequent visits.
When the flare is confirmed after 4 weeks, in both
treatment arms patients receive optimal treatment for
the flare, for example protocollised reinstallment or dose
increase of the TNF blocker or change to another bio-
logic or DMARD. Only patients in whom the flare per-
sist longer than three months (in spite of all treatment
intensivation) are classified as having persistent flare, the
primary outcome of this study.
Secondary outcomes
Cost effectiveness A separate calculation will be made
for the 9 months induction phase and the 12 months
maintenance phase for the reasons described above. The
cost analysis includes both direct and indirect costs,
from a society perspective, and consist of two main
components: determination of volumes of care and de-
termination of cost prices for each volume of consump-
tion. Volumes of care (registered out-patient clinic visits,
medication use, and work-related absenteeism) are
multiplied with the cost prices to calculate costs. Cost
prices for medication are retrieved from the Dutch Na-
tional tariff list provided by the Dutch Board of Health
Insurances. The standard cost prices from the ‘Dutch
Guideline for Cost Analyses’ are used for valuation of
hospital related care and work-related absenteeism.
Radiographic damage Change in radiographs of hands
and feet between baseline and study end are compared be-
tween intervention and usual care by calculating the
change in MSvdH score, scored chronologically in random
order [35]. The smallest detectable difference (SDD)
within this 18 months timeframe in this group of patients
with established RA is expected to be 8 points, compar-
able with the widely validated minimal clinical important
change (MCIC) of 5 point per year [38,39,41]. Proportions
of patients showing radiographic joint damage progression
exceeding the MCIC are then calculated.
Assessments
Regular visits are planned at baseline and every 3 months
thereafter up to month 18. When a flare occurs, patients
are seen within two days, but at least within a week, and
additionally an extra visit is planned after 4 weeks. In
Additional file 1: Table S1 we outlined all the visits and
assessments.
Randomisation, allocation concealment and blinding
Allocation is stratified for adalimumab and etanercept
using stratified block randomization in random sized
blocks and a ratio of 2:1. Patients will be randomised bythe research physician using a computer-generated ran-
domisation list, which has been transferred to paper
sheets and put in sealed envelopes.
This study uses a controlled and randomised, but only
partly blinded design, as patients and physicians are not
blinded for allocation. Blinding of the assessor perfor-
ming the joint scores was strived for, and this was done
by instructing both patients and the independent joint
assessor to first score the DAS28CRP, before assessing
medication changes and adverse effects.
Although triple blinding (patients, physicians, re-
searcher) would methodologically be preferable, this is
unfeasible because dose reduction in this study is done
via increasing the interval instead of decreasing the dos-
age per injection. The latter would not be sensible, since
TNF blockers are given using prefilled injection pens.
Blinding of patient and physician is possible when using
interval widening, but would be very difficult. The un-
blinded nature of the study could result in information
and attribution bias, as flares in patients in whom the
dose is reduced would possible be reported sooner be-
cause they would be attributed to the intervention. This
bias can however fortunately only lead to overestimation
of the drawbacks of a dose reduction strategy, not un-
derestimation, and therefore the higher risk of bias was
accepted.
Sample size
The null hypothesis in this study is that the intervention
is inferior compared to the control arm by more than
the non-inferiority margin δ (H0: μ1-μ2 > δ). The alterna-
tive hypothesis rejects this null hypothesis (H1: μ1-μ2 ≤ δ),
thus proving non-inferiority. The sample size calculation
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We estimated that 20% (p1 = 0.80) of patients will ex-
perience the primary outcome in the usual care arm
(persistent flare), with an estimated 15% (p2 = 0.85) of
patients with this outcome in the intervention arm. Apply-
ing one sided testing, an alpha of 0.05 (Zα = 1.64, non-
inferiority testing one sided), power 1-beta 0.8 (Zβ = 0.84),
an inferiority margin of 20% (δ = −0.2), and randomisation
ratio of 2:1 intervention versus control (k = 2) resulted in
n = 114 and n = 57 for intervention and control arm. Ac-
counting for a 10% drop-out, we choose to include 180
patients in total.
The estimation of proportion of primary outcome in
both groups and magnitude of the non-inferiority mar-
gin (δ) are motivated as follows. Although clear data are
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cluded a control group, and on previously published
drug survival curves for adalimumab and etanercept in
our population, we estimated that after 18 month in the
usual care group 15% of patients would have changed
their biologic therapy due to insufficient disease control
[12,15,16,28]. We furthermore assumed that 15% of pa-
tients in the intervention group can ultimately stop the
drug (without persistent flare), resulting in cumulative
incidence of 85% flares in the group of patients with
partial dose decrease. Of these patients, we estimate
that 5% will not respond to reinstallment of the TNF
blocker and experience a persistent flare. Thus, we expect
a cumulative incidence of persistent flare of 15 + 5 = 20%
in the intervention arm.
A difference in persistent flare of over 20% between
usual care and dose reduction would constitute a clinical
relevant non-inferiority margin in our opinion. The un-
derlying reasoning is, that it is to be expected that half
of the patients who start another biologic for a flare will
show response again within three months (21–23). Half
of 20% of the patients would therefore experience a per-
sistent flare, a more prolonged period with uncontrolled
disease activity, resulting in a NNH of 10. In our clinical
view, this seems to balance nicely with an expected
chance of being able to reduce the dose or stop the drug
of approximately 60 and 15% respectively (NNT 1.5 and
6 respectively), as much more patients are expected to
benefit than to be harmed using this non-inferiority
margin. The ratio of 2:1 for intervention and control
sample size is chosen to be able to include more de-
terminants in a prediction model for successful dose
reduction.
Planned data analysis
All statistical analyses are performed using STATA/IC
10.1 for Windows. Analyses will be done on intention to
treat (ITT) basis and also per protocol basis, the latter
because ITT analyses might underestimate differences
between treatment arms in non-inferiority studies, re-
sulting in a false positive study [25]. Number and rea-
sons for exclusion and dropout are reported to ensure
internal validity. Missing data on determinants/covari-
ates will be described using descriptive analyses and
missing data mechanisms will be studied. Missing values
will be imputed using multiple imputation when meeting
the assumption of missing (completely) at random, as
imputation will increase precision and possibly reduce
bias. Logistic regression models with the indicator vari-
able as outcome and the other variables as covariates
will be used to check these assumptions. Multiple im-
putation using chained equations will then be used to
estimate missing values. Descriptive statistics will be
provided using mean +/−SD, median (p25-p75) orfrequencies/percentages depending on the type distribu-
tion of the data.
The primary outcome, cumulative incidence of persist-
ent flare is calculated in both groups. The two propor-
tions are then compared using Fisher exact testing. The
cost and quality of life are compared between interven-
tion and usual care group for the induction phase and
for the maintenance phase separately. Direct costs and
indirect cost will be calculated, as will utility based on
EUROQOL-5D-5 L. Thereafter, when the intervention is
not a clearly dominated or dominant strategy, a decre-
mental cost effectiveness ratio will be estimated using
bootstrapping, expressed as saved costs divided by loss
in quality of life.
Discussion
The development of the current study protocol induced
a number of clinical and methodological issues that had
to be targeted, and that are specific for the context of
this research area. These choices include how to taper
the TNF blockers, the satisfactory control condition in
light of current treatment practices, how to define flare,
implementation in clinical practice, and the choice of
the non-inferiority margin. This resulted in a clinical
study design that differs in many respects from previ-
ously published and ongoing studies in this field.
In addition to the methodological issues mentioned
above, some medico-legal issues also arose. According to
new legislation based on GCP II, the 2001 EU directive
and the subsequent Dutch law on medical research
(WMO 2006), clinical studies that study patients using
medication, even when given according to current regis-
tration demands and not initiated or changed for study
purposes, are considered interventional medication stud-
ies [43,44]. This label results in a large administrative
burden (EUDRACT registration, investigators brochure,
increases monitoring demands, and responsibility for
medication cost), making investigator driven clinical
pharmacological research difficult or even nearly impos-
sible to perform. Paradoxically, this results in less safe
and (cost) effective care for the very people these laws
are meant to protect, the patients. Inspired by the dis-
cussion amongst clinical researchers concerning prac-
tical implications of this legislation, medical ethical
review boards have developed more lenient approaches
to these kind of studies [45,46]. Indeed, because our
study does not directly specify what medication to give,
but provides a comprehensive treatment strategy and
feedback as intervention, because the drugs are given for
standard indication, and as the intervention is with-
drawal of the drug, the study was considered not an
interventional medication study.
In conclusion, healthcare in the next decades will not
only be driven by improving outcomes, but also by
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for adverse effects. Non-inferiority studies combined
with decremental cost effectiveness analyses – although
thus far seldom done and challenging [25]–are the pref-
erential design to achieve this. The widespread and long
term use of expensive and sometimes toxic biologicals in
chronic inflammatory conditions seems an excellent field
to start with improving the cost effectiveness of our
current high cost healthcare system. Future research in
this topic should include expansion to other biologics and
other diseases.Additional file
Additional file 1: Table S1. Study visits and assessments.Abbreviations
ACR: America college of rheumatology; CRP: C-reactive protein;
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